Clinical Trial Update: Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 safety study of nifurtimox in patients with relapsed or refractory neuroblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Nifurtimox (Nifurtimox)

Snippet

Sponsor: University of Vermont | Conditions: Neuroblastoma | Phase 1 | Status: COMPLETED